Additionally, the eviction from the nucleus or the silencing of isoform c blocked tumor growth, highlighting the dominant oncogenic potential of isoform c and suggesting both canonical and alternative isoforms of ErbB-2 as therapeutic targets in TNBC [25]. Here, ERBB2 is linked to neoplasm.